Abstract
Precision medicine using the comprehensive genomic profiling (CGP) by next-generation sequencing is now introduced into clinical practice worldwide. In Japan, FoundationOne® CDx (F1CDx) was approved for the coverage by National Healthcare Reimbursement in 2019. The coverage is, however, only for patients with solid tumor refractory to or without standard chemotherapy. Many of those patients miss the chances to be enrolled into the clinical trials of new drugs because of their deteriorated physical condition.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
